ArticleScientific data2025
A clinical prostate biopsy dataset with undetected cancer.
Article in Scientific data, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Gene expression profiles in benign prostate tissue reflect tumor proximity, grade, and molecular subtype.Journal of translational medicine · 2026Article
- PTEN Protein Loss in Diagnostic Prostate Biopsies Is Associated with Gleason Score Upgrading in Radical Prostatectomy.Cancers · 2026Article
- In Vivo Prostate Cancer Modelling: From the Pre-Clinical to the Clinical Setting.Life (Basel, Switzerland) · 2026Review
- Longitudinal outcome prediction of prostate cancer patients on active surveillance using multiple instance learning.Journal of medical imaging (Bellingham, Wash.) · 2025Article
- Discovery of tumour indicating morphological changes in benign prostate biopsies through AI.Scientific reports · 2025Article
- Overdiagnosis and Overtreatment in Prostate Cancer.Diseases (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Prostate cancer is a heterogeneous disease showing variability both among individuals and within a patient. While most cases are indolent, aggressive tumors require early intervention. Accurately predicting tumor behavior is challenging, contributing to overdiagnosis but also undertreatment. Current imaging methods may miss the most malignant areas, leading to biopsies often capturing non-malignant prostate tissue even if cancer is present elsewhere in the organ. This non-malignant tissue, however, holds potential as a source for novel diagnostic and prognostic markers. Our clinical dataset comprises men with raised prostate-specific antigen but whose initial prostate needle biopsies only contained benign tissue. Half of the paired patients remained cancer-free for over eight years, while the others were diagnosed with prostate cancer within 30 months of follow-up. We share these initial benign biopsies to enable the exploration of morphological changes in non-malignant tissue and the potential for improved diagnostic accuracy in the early identification of patients with prostate cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.